Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026)
Korro Bio's (KRRO) quarterly Other Non-Current Assets came in at $2.5 million in Q2 2026, down 23.12% on a YoY basis from $3.2 million in Q2 2025, and up 2.53% quarter-over-quarter from $2.4 million in Q1 2026.
Analysis
Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has reported Other Non-Current Assets for 9 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets fell 23.12% year-over-year to $2.5 million; the trailing twelve-month figure through Jun 2026 stood at $2.5 million (down 23.12% YoY), and the FY2025 full-year result was $2.5 million, down 27.42% from the prior year.
- Other Non-Current Assets rose to $2.5 million in Q2 2026 per KRRO's latest filing, from $2.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7.0 million in Q4 2023 and bottomed at $1.7 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $3.0 million across 5 years, with a median of $2.8 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 202.77% in 2022, then slumped 51.13% in 2024.
- Over 5 years, Other Non-Current Assets stood at $5.1 million in 2022, then jumped by 35.48% to $7.0 million in 2023, then sank by 51.13% to $3.4 million in 2024, then fell by 27.42% to $2.5 million in 2025, then fell by 0.08% to $2.5 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.5 million, $2.4 million, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Korro Bio | 231.15 Mn | 116.12 Mn | - | 2.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.47 Mn |
| Mar 31, 2026 | 2.41 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Dec 31, 2024 | 3.41 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 6.97 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 1.96 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 5.14 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.70 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 1.70 Mn |
| Sep 30, 2021 | 1.73 Mn |